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Background
The aim of this study was to analyze the expression of
PD-L1 and MHC-I in 19 human tumor cell lines and
changes after interferon gamma (IFN-g) treatment, in
order to evaluate the potentiality of combining anti-PD-
L1 antibody with other immunotherapies.
Methods
Nineteen human tumor cell lines were cultured according
with ATCC guidelines: 5 colon (Caco-2, SW620, SW480,
Colo-205 and HT-29), 4 ovarian (OV-17, OVCAR-3, ES-2,
SKOV-3), 3 breast (MDA-MB-231, MCF-7, ZR-75), 3 lung
(H441, H1703, H460), 2 prostate (LnCap and PC-3), and 2
pancreatic (CFPAC-1 and ASPC-1). Cells were analyzed
by flow-cytometry for PD-L1 (clone 29E.2A3) and MHC-I
expression. The surface expression of PD-L1 was consid-
ered as low, medium, or high based on the percentage of
positive cells (80%, respectively). Cells were also analyzed
for PD-L1 mRNA expression by RT-PCR. Experiments
were performed with or without IFN-g pre-treatment
(10 ng/ml, 24 hours).
Results
The expression of PD-L1 was as follows. Low: 4/5 colon
(SW620, SW480, Colo-205 and HT-29), 1/4 ovarian
(OVCAR-3), 2/3 breast (ZR-75, MCF-7), and 1/2 pancrea-
tic (ASPC-1). Medium: 1/5 colon (Caco-2), 2/4 ovarian
(OV-17, SKOV-3), 2/3 lung (H460, H1703), and 1/2 pros-
tate (LnCap). High: 1/4 ovarian (ES-2), 1/3 lung (H441),
and 1/2 prostate (PC-3), 1/3 breast (MDA-MB-231), and
1/2 pancreatic (ASPC-1). After IFN-g pre-treatment, 14/19
cell lines showed a >50% increase of PD-L1 and 14/19 a
>50% increase of MHC-I (either percentage positive or
MFI). In 13/19 cell lines both markers increased. IFN-g
pre-treatment caused an increase >100% of PD-L1 mRNA
expression in 14/19 cell lines. CFPAC-1 (pancreatic)
showed an increase of surface PD-L1 without mRNA
change; on the opposite, H1703 (lung) showed mRNA
increase without changes in surface expression.
Conclusions
Tumor cells express different percentage of PD-L1 and
MHC-I in their surface. In most of the cells analyzed,
both molecules are increased by exposure to IFN-g.
Based on these observations, immunotherapies aiming
to increase IFN-g in the tumor microenvironment, such
as therapeutic vaccines or T cell adoptive transfer, can
facilitate immune recognition of tumor cells by an
increase of MHC-I on the surface of tumor cells. On
the other hand, the increased PD-L1 expression in the
tumor can be an ideal target for anti-PD-L1 antibody
treatment.
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